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OBJECTIVES: To explore the clinical significance and correlation of microRNA-21 (miR-21) and the neutrophil-
lymphocyte ratio (NLR) in patients with acute myocardial infarction (AMI).
METHODS: The observation group contained 184 patients, while the control group contained 150 patients.
The expression of miR-21 in the serum of each group was detected by qRT-PCR.
RESULTS: A total of 184 patients and their family members were followed-up for 30 days, among which
35 patients died and 149 patients survived, resulting in a survival rate of 80.97%. According to univariate
analysis, there were significant differences in age, cardiac troponin (cTn), heart rate, Killip grade, percutaneous
coronary intervention (PCI) operation rate, miR-21 and NLR. In the receiver operating characteristic (ROC)
analysis, the area under the curve (AUC) values of miR-21 and NLR for the diagnosis of AMI were 0.909 and
0.868, respectively, and the area under the combined detection curve was 0.960. In the Kaplan-Meier survival
analysis, the survival of patients with high miR-21 expression and NLR was significantly higher than that of
patients with low miR-21 expression and NLR (p=0.027; p=0.001). The correlation showed that miR-21 expression
in serum was positively correlated with the NLR in the observation group (r=0.528, po0.05). cTn, heart rate,
Killip classification, PCI operation rate, miR-21, NLR are independent risk factors for AMI.
CONCLUSION: miR-21 and NLR play a role in the diagnosis of AMI and can be used as predictors for the survival
of AMI.
KEYWORDS: Acute Myocardial Infarction; miR-21; NLR; ROC.
’ INTRODUCTION
Cardiovascular disease (CVD) is the most commonly
occurring disease with the highest morbidity (1). The study
by Go et al. (2) estimated that the mortality of CVD will
increase to 36.6% worldwide by 2020, causing great harm to
the lives and health of people. Other studies (3) indicated that
there is a close relationship between CVD and atherosclerosis
(AS). Patients with AS are prone to acute myocardial infarction
(AMI), the main cause of which is coronary AS leading to
stenosis of the vascular lumen, myocardial ischemia, hypoxia
and myocardial damage. Boersma et al. (4) indicated that there
were approximately 3 million new cases of patients with AMI
worldwide every year. At present, cardiac troponin (cTn) is the
main detection index for AMI and is recognized as the ‘‘gold
diagnostic standard’’ (5). White et al. (6) demonstrated that the
expression of cTn in the blood of patients with end-stage renal
disease is elevated, which can be used as a biomarker of renal
failure. Similarly, finding better biomarkers for the diagnosis of
AMI is particularly important.
MicroRNAs (miRNAs) are a kind of noncoding short-
chain RNA that are approximately 22 nucleotides in length.
The main function of miRNAs is to inhibit the translation
and transcription of target genes by binding to the 3’
untranslated region (UTR) of its downstream target gene
mRNA, thus changing the expression of the target gene (7).
Studies (8-10) have shown that miRNAs have regulatory
effects in various diseases, such as tumors and cardiovas-
cular diseases, as well as in altering neurological function. As
one of the most widely studied miRNAs in recent years, miR-
21 plays an important role in embryonic development,
tumors, immune response and osteogenic differentiation (11).
Dong et al. (12) showed that miR-21 was expected to be a
potential diagnostic indicator of AMI instead of a predictor
of death in AMI. In recent years, many studies have
suggested that the neutrophil-lymphocyte ratio (NLR) is ofDOI: 10.6061/clinics/2019/e1237
Copyright & 2019 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on March 21, 2019. Accepted for publica-
tion on July 17, 2019
1
ORIGINAL ARTICLE
great value in predicting coronary artery disease (13). Nilsson
et al. (14) indicated that the higher the expression of the NLR is
in non-ST-segment elevation myocardial infarction, the higher
the rate of atheromatous plaque. Stakos et al. (15) demon-
strated that the NLR could be used as an independent risk
factor for thrombosis, in-stent restenosis, percutaneous trans-
luminal coronary angioplasty (PTCA), coronary artery bypass
graft, posterior coronary atherosclerotic plaque rupture and
other CVDs.
Therefore, this study aimed to analyze the expression of
miR-21 and NLR in patients with AMI to determine whether
they can be used as indicators for the diagnosis and survival
assessment of AMI, thereby providing a reference for the
diagnosis and survival prediction of AMI.
’ MATERIALS AND METHODS
Clinical data of patients
A total of 184 patients with AMI treated at our hospital
were allocated the observation group in this study, including
124 male patients and 60 female patients, aged 27 to 88 years,
with a mean age of 59.0±9.4 years. In addition, 150 patients
were allocated to the control group, including 102 male
patients and 48 female patients, aged 29 to 89 years, with a
mean age of 60.4±11.5 years. The study was approved by
the medical ethics committee of the Daqing Longnan
Hospital. All patients signed an informed consent form.
Inclusion of exclusion criteria
The inclusion criteria were as follows. Patients were admit-
ted to the hospital within 6 hours. The diagnostic criteria of
AMI were based on the diagnostic guidelines for AMI issued
by the American Heart Association (AHA) in 2003 (16). The
marker for diagnosis of myocardial necrosis significantly
increased. Patients with complete clinical data accepted the
treatment and follow-up study.
The exclusion criteria were as follows: patients with con-
genital immunodeficiency, acute infectious diseases, valvular
heart diseases, malignant tumors, liver and kidney dysfunc-
tion, a history of severe bleeding, severe bleeding, and
antiplatelet aggregation therapy.
Main kits and instruments
A hematology analyzer (Siemens, Germany, ADVIA2120i),
a PCR system (ABI Company, USA, 7500), a Total RNA Ext-
raction Kit, an EasyPure miRNA Kit, a Reverse transcription
+PCR Kit, and the TransScript miRNA First-Strand cDNA
Synthesis SuperMix (TransGen Biotech, Beijing, China,
ER601-01, AT351-01) were used. The miR-21 primers were
synthesized by Shanghai Sangon Biotech Co., Ltd. (Table 1).
’ METHODS
Patients after treatment
Patients diagnosed with AMI were treated with 300 mg
aspirin +300 mg clopidogrel or 180 mg ticagrelor.
Specimen collection
Eight milliliters of fasting venous blood was collected from
patients who received a physical examination. Eight milli-
liters of abdominal venous blood was collected from patients
in the observation group. The collected blood samples were
placed in EDTA anticoagulant tubes (3 mL) and inert sepa-
ration gels and coagulant tubes (5 mL). The expression of
NLR in venous blood in the EDTA anticoagulant tubes
was detected by flow cytometry. The venous blood in inert
separation gels and coagulant tubes was centrifuged at
3000 rpm and 24oC for 10 min to collect the serum for the
next step, and the remaining sample was placed in an EP
tube without RNA enzymes at -80oC.
PCR detection
An EasyPure miRNA Kit was used to extract total RNA.
Total RNA was extracted by an ultraviolet spectrophot-
ometer, and agarose gel electrophoresis (AGE) was used to
determine the purity, concentration and integrity of the total
RNA. TransScripts miRNA RT Enzyme Mix and 2TS
miRNA Reaction Mix were used to reverse transcribe the
total RNA according to the manufacturer’s instructions. PCR
amplification experiments were carried out. The PCR system
was as follows: 1 mL of cDNA, 0.4 mL of upstream and down-
stream primers, 10 mL of 2TransTaqs Tip Green qPCR
SuperMix, 0.4 mL of Passive Reference Dye (50 ) and 20 mL
of ddH2O. The PCR conditions were as follows: predena-
turation at 94oC for 30s, denaturation at 94oC for 5s, ann-
ealing at 60oC for 30s, with a total of 40 cycles. Three replicate
wells were set for each sample, and the experiment was
performed three times. In this study, U6 was used as an
internal reference, and the 2-Wct method was used to analyze
the data.
Observation index
The main outcome measures were as follows. The expres-
sion levels of miR-21 and NLR were compared between the
observation group and the control group. Survival at 30 days
after admission was calculated. According to the survival of
patients, the risk factors for death were analyzed by multi-
variate logistic regression. Pearson’s test was used to analyze
the correlation between miR-21 and NLR in the serum of the
observation group.
The secondary outcome measures were as follows. Receiver
operating characteristic (ROC) curves were used to analyze
the diagnostic values and best cut-off values of miR-21 and
NLR in patients with AMI. The best cut-off values of miR-21
and NLR were used to divide patients into high- and low-
expression groups to observe the survival of patients in 30
days and plot the Kaplan-Meier (K-M) curve.
Statistical analysis
In this study, the SPSS 20.0 (Shanghai Cabit Information
Technology Co., Ltd., China) software package was used to
analyze the collected data. GraphPad Prism 7 (Shenzhen
Softhead Software Technology Co., Ltd., China) was used to
plot the data. The count data were assessed by chi-square test
(w2). The Kolmogorov–Smirnov (K-S) test was used to ana-
lyze the distribution of the data. The measurement data are
expressed as the means ± standard deviations (SDs). The
normally distributed data were compared by independent
sample t test. The rank data were assessed by the rank sum
test. The nonparametric test was used for the nonnormally
Table 1 - Primer sequences.
Gene Upstream primer Downstream primer
miR-21 5’-ACACTCCAGCTGGGTA
GCTTATCAGACTGAT-3’
5’-ACTGGTGTCGTGGAGT
CG-3’
U6 5’-CTCGCTTCGGCAG
CACA-3’
5’-AACGCTTCACGAATTTG
CGT-3’
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distributed data. Pearson’s test was used to analyze the rela-
tionship between miR-21 and NLR in the serum of the obser-
vation group. The ability of miR-21 and NLR to diagnose
AMI was evaluated by ROC analysis. K-M survival curves
and the log rank test were used to analyze the 30-day
survival of patients. po0.05 indicated a statistically signifi-
cant difference.
’ RESULTS
Clinical data of the patients
According to the clinical data, there were 124 male patients
and 60 female patients in the observation group, with an
average age of 59.0±9.4 years and an average BMI of 23.15
kg/m2. Among these patients, 55 had hypertension, 12 had
diabetes, 24 had hyperlipidemia, 16 had chronic obstructive
pulmonary disease (COPD), 130 had a history of smoking,
and 20 had a history of alcoholism. A total of 152 patients
were urban residents, and 32 were rural residents. There
were 102 male patients and 48 female patients in the control
group, with an average age of 60.4±11.5 years and an
average BMI of 23.04 kg/m2. Among these patients, 39 had
hypertension, 14 had diabetes, 23 had hyperlipidemia, 10
had COPD, 115 had a history of smoking, and 11 had a
history of alcoholism. A total of 130 patients were urban resi-
dents, and 20 were rural residents. There was no significant
difference between the two groups (p40.05). There was
no difference in total cholesterol, triglyceride, low-density
lipoprotein, creatinine or urea nitrogen concentration between
the two groups (p40.05). The concentration of cTn in the
observation group was significantly higher than that in the
control group (po0.05) (Table 2).
Expression of miR-21 and NLR in the observation
group and control group
Regarding the expression of miR-21 and NLR in the two
groups, the expression of miR-21 and NLR in the observation
group was significantly higher than that in the control group
(po0.05) (Figure 1).
Diagnostic value of miR-21 and NLR in AMI
ROC curves were plotted to analyze the diagnostic value
of miR-21 and NLR in AMI between the observation group
and the control group. The area under the curve (AUC) of
miR-21 was 0.909 (95% CI: 0.877B0.941). The AUC of NLR
was 0.868 (95% CI: 0.830B0.906). The AUC of the combined
detection curve was 0.960 (95% CI: 0.943B0.978) (Figure 2
and Table 3).
Survival of patients
For the 30-day survival of the patients in the observation
group, 184 patients were followed-up, among which 35
patients died within 30 days and 149 patients survived,
resulting in a survival rate of 80.97% (Figure 3).
Diagnostic value of miR-21 and NLR for AMI
ROC curves were used to analyze miR-21 and NLR in the
diagnosis of AMI according to the survival and death of
patients. The AUC of miR-21 was 0.617 (95% CI: 0.517-0.719).
The AUC of NLR was 0.654 (95% CI: 0.552B0.755). The
AUC of the combined detection curve was 0.692 (95% CI:
0.597B0.787) (Figure 4 and Table 4).
Relationship between miR-21 expression and the
NLR and the 30-day survival of patients
High and low-expression groups were established accord-
ing to the cut-off value of the ROC curve of miR-21 and NLR
for the survival of AMI patients. Based on the K-M survival
curve, the 30-day survival of patients with high miR-21
expression was significantly lower than that of patients with
low miR-21 expression (p=0.027). Based on the NLR of the
two groups, the 30-day survival of patients with a high NLR
was significantly lower than that of patients with a low NLR
(p=0.001) (Figure 5).
Univariate analysis of patient survival
According to the survival status of the two groups,
patients were divided into the survival group (n=149) and
Table 2 - Clinical data of patients.
Factor Observation group (n=184) Control group (n=150) t/2/Z value p-value
Sex Male 124 (67.39) 102 (68.00) 0.014 0.906
Female 60 (32.61) 48 (32.00)
Age (years) 59.0±9.4 60.4±11.5 1.224 0.222
BMI (kg/m2) 23.15±1.82 23.04±1.97 0.529 0.567
Anamnesis
Hypertension 55 (29.89) 39 (41.49) 0.619 0.432
Diabetes mellitus 12 (6.52) 14 (9.33) 0.910 0.340
Hyperlipemia 24 (13.04) 23 (15.33) 0.358 0.549
COPD 16 (8.70) 10 (6.67) 0.474 0.491
Smoking history Yes 130 (70.65) 115 (76.67) 1.529 0.216
No 54 (29.35) 35 (23.33)
History of alcoholism Yes 20 (10.87) 11 (7.33) 1.227 0.268
No 164 (89.13) 139 (92.67)
Domicile City 152 (82.61) 130 (86.67) 1.035 0.309
Village 32 (17.39) 20 (13.33)
Total cholesterol (mmol/L) 4.45±1.10 4.23±0.94 1.939 0.053
Glycerin trilaurate (mmol/L) 1.91±0.93 1.84±0.0.7 0.762 0.446
LDL (mmol/L) 2.56±0.87 2.44±0.76 1.326 0.186
Creatinine (mmol/L) 71.44±11.90 70.18±11.02 0.995 0.320
Urea nitrogen (mmol/L) 6.24±1.52 6.15±1.06 0.614 0.540
cTn (ng/mL) 0.69±0.35 0.09±0.06 o0.001
Note: COPD: chronic obstructive pulmonary disease
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the death group (n=35). The univariate analysis based on the
clinical data showed that there was no difference in sex, BMI,
past medical history, smoking history, history of alcoholism,
place of residence, total cholesterol, triglyceride, low-density
lipoprotein, creatinine and urea nitrogen between the two
groups (p40.05). However, there were significant differences
in age, cTn, heart rate, Killip classification, percutaneous
coronary intervention (PCI) operation rate, miR-21 and NLR
(po0.05) (Table 5).
Multivariate analysis of patient survival
The index of the variables with significant differences in
the univariate analysis are shown in Table 6. Then, multi-
variate logistic regression analysis was performed. The
results showed that age was not an independent risk factor
for the survival of patients. However, cTn (OR: 6.435, 95% CI:
1.342B30.861), heart rate (OR: 1.072, 95% CI: 1.033B1.111),
Killip classification (OR: 6.784, 95% CI: 2.265B20.324), PCI
operation rate (OR: 0.309, 95% CI: 0.117B0.819), miR-21 (OR:
0.315, 95% CI: 0.118B0.835), and NLR (OR: 0.310, 95% CI:
0.120B0.799) were independent risk factors in patients with
AMI (Table 7).
Figure 2 - ROC curve of miR-21 and NLR for the diagnosis of AMI.
Figure 1 - Expression of miR-21 and the NLR in the observation group and the control group. The NLR in the peripheral blood of the
patients in the observation group was significantly higher than that in the patients in the control group (po0.05). The expression of
miR-21 in the serum of the patients in the observation group was significantly higher than that of the patients in the control group
(po0.05). *The expression of miR-21 was significantly higher in the observation group than in the control group (po0.001).
Table 3 - ROC curve data.
Index AUC 95% CI Specificity Sensitivity Youden index Cut-off
miR-21 0.909 0.877B0.941 85.33% 84.66% 69.99% o1.165
NLR 0.868 0.830B0.906 77.17% 84.66% 61.84% o3.035
Joint detection 0.960 0.943B0.978 90.23% 89.33% 79.55% o0.500
Note: AUC: area under the curve; Cut-off: intercept
Figure 3 - The survival of the patients was followed up for 30
days. The total survival rate at 30 days was 80.97.
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Correlation between miR-21 and NLR in the
observation group
Regarding the relationship between miR-21 and NLR,
miR-21 expression was positively correlated with NLR in the
observation group; that is, the higher the NLR is, the higher
expression of miR-21 (r=0.528, p=0.001) (Figure 6).
’ DISCUSSION
As the most common clinical disease, AMI is characterized
by a high incidence, high hospitalization rate and high mor-
tality (17). Patients suffer from AMI because of the imbalance
between the supply and demand of the myocardial cell
energy supply, which leads to myocardial cell necrosis, or
even cardiac dysfunction (18). At present, early diagnosis is
the main treatment for patients with AMI. Revascularization
can improve the condition of patients. Thus, the early
diagnosis of AMI is particularly important. Currently, the
diagnosis of AMI includes the observation of vital signs,
imaging examination and traditional hematological exam-
ination. The presence of chest pain is an important feature for
diagnosing AMI (19). However, traditional hematological
tests, such as cTnI and CK-MB, have time limitations. In the
early stage, the test results are negative and are determined
by repeated measurements, which not only delay treatment
but also increase the economic burden of patients (20).
As a hot topic of research in recent years, miRNAs have
attracted the attention of many scholars. miRNAs are small
noncoding RNAs approximately 21-25 nucleotides in length
and are involved in cellular and physiological processes,
such as the regulation of cells, energy metabolism and
apoptosis. When a miRNA is bound to the 3’UTR of the
downstream target gene, the mRNA is degraded, and the
translation of the protein is inhibited (21). Many studies have
indicated that multiple miRNAs are differentially expressed
during the development of AMI (22,23). Specifically, miR-21
is an important miRNA. Previous studies have shown that
miR-21 is differentially expressed between the serum of
patients with AMI and that of normal people. Other studies
have shown that miR-21 plays an important role in a variety
of CVDs (24). Oerlemans et al. (25) indicated that the AUC of
miR-21 combined with high-sensitivity troponin T for the
diagnosis of acute coronary syndrome was found to be more
than 0.9 by detecting the expression of miR-21 in 332
suspected acute coronary syndrome patients. However, few
studies have shown that miR-21 can be used as a predictor of
death in AMI. In this study, by detecting the expression of
miR-21 in the plasma of the observation group and the
control group, the expression of miR-21 in the serum of the
observation group was found to be significantly increased.
Zhang et al. (26) showed that the overexpression of miR-21 in
serum can be used as a diagnostic indicator of acute ischemic
heart disease. In addition, there was a difference in the expres-
sion of miR-21 between patients with AMI and normal
patients, suggesting that miR-21 may be a potential diagnostic
Figure 4 - ROC curve of miR-21 and NLR for the diagnosis of AMI
death.
Table 4 - Diagnostic value of miR-21 and NLR in AMI death.
Index AUC 95% CI Specificity Sensitivity Youden index Cut-off
miR-21 0.617 0.517B0.719 80.00% 40.94% 20.94% o1.265
NLR 0.654 0.552B0.755 54.29% 75.84% 30.12% o4.245
Joint detection 0.692 0.597B0.787 68.77% 67.78% 36.36% o0.208
Note: AUC: area under the curve; Cut-off: intercept
Figure 5 - The relationship between the expression of miR-21 and
NLR and the survival of patients at 30 days. A. The survival rate of
patients was found to be significantly lower in the miR-21 high-
expression group than in the low-expression group, and there
was a significant difference between the high-expression group
and the low-expression group. B. The survival rate of the NLR
high-expression group was significantly lower than that of the
low-expression group. There was a significant difference in 30-
day survival.
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indicator of AMI. According to the ROC curve, the AUC of
miR-21 was 0.909, indicating that miR-21 can be used as a
biomarker of AMI. The NLR is an effective and inexpensive
diagnostic indicator of inflammation. Some studies have
shown that the NLR is not only involved in the process of
AS but is also closely related to clinical events, such as
atherosclerotic plaque collapse (27). In recent years, studies
have demonstrated that the NLR has an outstanding effect on
the diagnosis of AMI and can be used as a prognostic indi-
cator for coronary heart disease (28,29). Therefore, this study
detected the NLR in the plasma of patients with AMI and
found that the NLR in the observation group was significantly
higher than that in the control group. Aya et al. (30) suggested
that the NLR in the blood of patients with ST-segment
elevation myocardial infarction was significantly increased,
which was consistent with our findings. According to the
ROC curve, the AUC of NLR was 0.868, suggesting that the
NLR has a certain value in the diagnosis of AMI. Based on the
combined ROC curve of NLR and miR-21, the AUC was
0.960. When the cut-off value was 0.500 or below, the spe-
cificity and sensitivity were 90.23% and 89.33%, respecti-
vely, which were significantly higher than that of the single
detections.
Furthermore, a follow-up study was conducted on the 30-
day survival of the patients in the observation group. A total
of 184 patients were included the follow-up study, of which
35 patients died and 149 patients survived within 30 days,
with a survival rate of 80.97%. The patients were divided
according to their survival status, and the diagnostic value of
the NLR and miR-21 expression in patients who died from
AMI was predicted by the ROC curve. The AUC of miR-21
was 0.617. The two indicators showed that the cut-off
value was 1.265 or below, and the specificity and sensitivity
were 80.00% and 40.94%, respectively. The AUC of NLR was
0.654. When the cut-off value was 4.245, the specificity and
sensitivity were 54.29% and 75.84%, respectively. Given that
differences existed in the sensitivity and specificity of these
two indices, the AUC of the combined detection was 0.692.
When the cut-off value was 0.208 or below, the specificity
and sensitivity were 68.77% and 67.78%, respectively, which
indicated that the combined detection could complement the
defects. Moreover, patients were divided into high and low-
expression groups according to the cut-off value. According
to the K-M survival curve, the 30-day survival of patients
with high NLR and miR-21 expression was significantly
lower than that of patients with low NLR and miR-21
expression. According to multivariate logistic regression
Table 5 - Single-factor analysis.
Factor Survival group (n=149) Death group (n=35) t/2/Z value p-value
Sex Male 99 (66.44) 25 (71.43) 0.320 0.571
Female 50 (33.56) 10 (28.57)
Age (years) X60 59 (39.60) 24 (68.57) 9.609 0.002
o60 90 (60.40) 11 (31.43)
BMI (kg/m2) 23.55±1.34 23.06±1.90 1.786 0.076
Anamnesis
Hypertension 44 (28.76) 11 (27.50) 0.025 0.875
Diabetes mellitus 9 (6.04) 3 (8.57) 0.298 0.585
Hyperlipemia 19 (12.75) 5 (14.29) 0.059 0.808
COPD 12 (9.40) 4 (11.43) 0.133 0.716
Smoking history Yes 103 (69.13) 27 (77.14) 0.878 0.349
No 46 (30.87) 8 (22.86)
History of alcoholism Yes 16 (10.74) 4 (11.43) 0.014 0.906
No 133 (89.26) 31 (88.57)
Domicile City 122 (81.88) 30 (85.71) 0.290 0.590
Village 27 (18.12) 5 (14.29)
Total cholesterol (mmol/L) 4.62±1.11 4.42±1.10 0.961 0.338
Glycerin trilaurate (mmol/L) 2.03±0.87 1.87±0.94 0.964 0.336
LDL (mmol/L) 2.36±0.79 2.60±0.88 1.582 0.115
Creatinine (mmol/L) 69.42±11.82 71.91±11.90 1.12 0.264
Urea nitrogen (mmol/L) 6.41±1.72 6.19±1.47 0.699 0.486
cTn (ng/mL) 0.66±0.34 0.83±0.34 2.662 0.009
Heart rate (?/min) 82.45±13.32 94.66±15.82 4.703 o0.001
Killip classification XLevel 3 16 (10.74) 15 (42.86) 20.871 o0.001
oLevel 3 133 (89.26) 20 (57.14)
PCI operation rate Yes 92 (61.74) 15 (42.86) 4.155 0.042
No 57 (38.26) 20 (57.14)
miR-21 o1.265 109 (73.15) 19 (54.29) 4.766 0.003
X1.265 40 (26.85) 16 (45.71)
NLR o 4.245 114 (76.51) 15 (42.85) 15.32 o0.001
X4.245 35 (23.49) 20 (57.14)
Table 6 - Assignment table.
Factor Assignment
Age X60 years = 1, o60 years =0
cTn Data are continuous variables using raw data
analysis
Heart rate Data are continuous variables using raw data
analysis
Killip classification XLevel 3 =1, o Level 3 =0
PCI operation rate Yes=1, No=0
miR-21 o1.435=1, X1.435=0
NLR o4.245=1, X4.245=0
Death status Death=1, Survival =0
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analysis, the low expression of miR-21 and NLR were pro-
tective factors for death of patients, indicating that the
expression of miR-21 and NLR in patients can be used as a
predictor of 30-day survival in patients with AMI.
Furthermore, Pearson’s test was used to detect the
correlation between miR-21 and NLR in the observation
group. The expression of miR-21 was positively correlated
with the NLR, suggesting that a close relationship existed
between miR-21 and the NLR. However, this study still has
some limitations. First, the detection of miR-21 is more
expensive than that of NLR. Long-term detection increases
the economic burden of patients. Second, the relationship
between miR-21 and NLR in clinical experiments is unclear.
Relevant experiments in future research will be added to
explore the relationship between miR-21 and NLR and prove
the results of the research.
’ CONCLUSIONS
In summary, cTn, heart rate, Killip classification, PCI
operation rate, miR-21 and NLR are independent factors for
death in patients with AMI. There is a positive correlation
between miR-21 and NLR, which can be used as a predictor
of the diagnosis and death of patients with AMI.
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